Last reviewed · How we verify
miFL + bevacizumab
miFL is a monoclonal antibody that targets bevacizumab, a vascular endothelial growth factor A (VEGF-A) inhibitor.
miFL is a monoclonal antibody that targets bevacizumab, a vascular endothelial growth factor A (VEGF-A) inhibitor. Used for Metastatic non-small cell lung cancer, PD-L1 positive, Metastatic colorectal cancer.
At a glance
| Generic name | miFL + bevacizumab |
|---|---|
| Sponsor | Pfizer |
| Drug class | VEGF inhibitor |
| Target | VEGF-A |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
miFL works by binding to bevacizumab, preventing it from inhibiting VEGF-A. This allows VEGF-A to promote angiogenesis, which is essential for tumor growth and metastasis. By inhibiting bevacizumab, miFL may help to improve treatment outcomes in certain types of cancer.
Approved indications
- Metastatic non-small cell lung cancer, PD-L1 positive
- Metastatic colorectal cancer
Common side effects
- Fatigue
- Hypertension
- Nausea
Key clinical trials
- Trial Of Irinotecan In Combination With Three Methods Of Administration Of Fluoropyrimidine. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- miFL + bevacizumab CI brief — competitive landscape report
- miFL + bevacizumab updates RSS · CI watch RSS
- Pfizer portfolio CI